换一批An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
第一作者：
Gabriella,Parma
第一单位：
Division of Gynaecology, Istituto Europeo di Oncologia (IEO), Milan, Italy.
作者：
医学主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);硼酸化物(Boronic Acids);CA-125抗原(CA-125 Antigen);癌, 乳头状(Carcinoma, Papillary);囊腺癌, 浆液(Cystadenocarcinoma, Serous);多柔比星(Doxorubicin);抗药性, 肿瘤(Drug Resistance, Neoplasm);子宫内膜肿瘤(Endometrial Neoplasms);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);肿瘤分期(Neoplasm Staging);卵巢肿瘤(Ovarian Neoplasms);腹膜肿瘤(Peritoneal Neoplasms);铂(Platinum);聚乙烯二醇类(Polyethylene Glycols);预后(Prognosis);吡嗪类(Pyrazines);回顾性研究(Retrospective Studies);挽救疗法(Salvage Therapy);存活率(Survival Rate);青年人(Young Adult)
DOI
10.1097/IGC.0b013e318251051a
PMID
22635029
发布时间
2025-04-28
- 浏览8
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
